📊 RGBPP Key Takeaways
Is RGBPP a Good Investment? Thesis Analysis
Regen BioPharma exhibits severe financial distress with negative stockholders' equity of -6.6M, indicating technical insolvency. The company faces an acute liquidity crisis with only 4.6K in cash against 6.8M in liabilities and a current ratio of 0.03x, while continuing to burn 197.9K in operating cash flow with near-zero revenue generation of 59.1K.
Why Buy RGBPP? Key Strengths
- Minimal revenue base provides potential runway for operational restructuring
- No explicit long-term debt obligations limiting structured default risk
- Small operating cost structure reduces absolute capital requirements for survival
RGBPP Investment Risks to Consider
- Negative shareholders' equity of -6.6M indicates technical insolvency and negative book value
- Critical liquidity crisis: 4.6K cash against 6.8M liabilities with 0.03x current ratio suggests imminent solvency risk
- Severe cash burn of 197.9K operating cash flow with stalled revenue at 59.1K (0% YoY growth) creates unsustainable funding gap
- Net losses deteriorating sharply at -967.9K with -90.7% YoY decline indicating worsening operational performance
- No insider activity in past 90 days suggests complete loss of management confidence
- Extreme negative margins (-933.9% operating, -1638.6% net) indicate fundamental business model failure
Key Metrics to Watch
- Cash runway and days of liquidity remaining before insolvency
- Revenue growth rate and product commercialization milestones
- Monthly operating cash burn trend and path to cash flow break-even
- Stockholders' equity trajectory and debt restructuring activities
- Insider transactions as indicator of management confidence
- Quarterly net loss magnitude and operating expense reduction progress
RGBPP Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RGBPP Profitability Ratios
RGBPP vs Healthcare Sector
How Regen BioPharma Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RGBPP Overvalued or Undervalued?
Based on fundamental analysis, Regen BioPharma Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RGBPP Balance Sheet & Liquidity
RGBPP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Regen BioPharma Inc's revenue has shown modest growth of 0% over the 5-year period. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
RGBPP Growth Metrics (YoY)
RGBPP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.1K | -$515.4K | $-0.01 |
| Q3 2025 | $59.1K | -$130.1K | $-0.01 |
| Q2 2025 | $59.1K | -$19.4K | $0.00 |
| Q1 2025 | $59.1K | -$144.9K | $-0.04 |
| Q3 2024 | $31.6K | -$99.2K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RGBPP Capital Allocation
RGBPP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Regen BioPharma Inc (CIK: 0001589150)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGBPP
What is the AI rating for RGBPP?
Regen BioPharma Inc (RGBPP) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGBPP's key strengths?
Claude: Minimal revenue base provides potential runway for operational restructuring. No explicit long-term debt obligations limiting structured default risk.
What are the risks of investing in RGBPP?
Claude: Negative shareholders' equity of -6.6M indicates technical insolvency and negative book value. Critical liquidity crisis: 4.6K cash against 6.8M liabilities with 0.03x current ratio suggests imminent solvency risk.
What is RGBPP's revenue and growth?
Regen BioPharma Inc reported revenue of $59.1K.
Does RGBPP pay dividends?
Regen BioPharma Inc does not currently pay dividends.
Where can I find RGBPP SEC filings?
Official SEC filings for Regen BioPharma Inc (CIK: 0001589150) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGBPP's EPS?
Regen BioPharma Inc has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGBPP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Regen BioPharma Inc has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGBPP stock overvalued or undervalued?
Valuation metrics for RGBPP: ROE of N/A (sector avg: 15%), net margin of -1,638.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGBPP stock in 2026?
Our dual AI analysis gives Regen BioPharma Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGBPP's free cash flow?
Regen BioPharma Inc's operating cash flow is $-197.9K, with capital expenditures of N/A. FCF margin is -335.1%.
How does RGBPP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,638.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).